Studying c-Myc serine 62 phosphorylation in leukemia cells: concern over antibody cross-reactivity
- 31 May 2012
- journal article
- Published by American Society of Hematology in Blood
- Vol. 119 (22) , 5334-5335
Abstract
To the editor: A recent article in Blood demonstrated that the Pim kinase inhibitor SGI-1776 has efficacy in acute myeloid leukemia.[1][1] This inhibitor reduced phosphorylation of multiple targets of the Pim kinases, including c-Myc at serine 62 (S62). Because no therapies directly target c-Myc,Keywords
This publication has 9 references indexed in Scilit:
- Mechanistic insight into Myc stabilization in breast cancer involving aberrant Axin1 expressionProceedings of the National Academy of Sciences, 2011
- Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemiaBlood, 2011
- Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformationProceedings of the National Academy of Sciences, 2009
- A Conserved Pathway That Controls c-Myc Protein Stability through Opposing Phosphorylation Events Occurs in YeastJournal of Biological Chemistry, 2007
- Aberrant stabilization of c-Myc protein in some lymphoblastic leukemiasLeukemia, 2006
- Protein Phosphatase 2A Regulatory Subunit B56α Associates with c-Myc and Negatively Regulates c-Myc AccumulationMolecular and Cellular Biology, 2006
- c-Myc Phosphorylation Is Required for Cellular Response to Oxidative StressMolecular Cell, 2006
- A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cellsNature Cell Biology, 2004
- Multiple Ras-dependent phosphorylation pathways regulate Myc protein stabilityGenes & Development, 2000